Brief: Ocuphire Pharma Announces Financial Results For First Quarter 2023 And Provides Corporate Update

Opus Genetics

15/05/2023 13:14

Ocuphire Pharma Inc  OCUP.O :
    * OCUPHIRE PHARMA ANNOUNCES FINANCIAL RESULTS FOR FIRST
QUARTER
2023 AND PROVIDES CORPORATE UPDATE
    * CASH BALANCE OF $39 MILLION EXPECTED TO FUND OPERATIONS
INTO
2025
    * OCUPHIRE PHARMA - END-OF-PHASE 2 MEETING WITH FDA
ANTICIPATED IN
2H 2023 TO CONFIRM PHASE 3 REGULATORY PATH FOR ORAL APX3330 IN
DIABETIC RETINOPATHY
    * PDUFA DATE FOR NYXOL FIRST INDICATION IN REVERSAL OF
PHARMACOLOGICALLY-INDUCED MYDRIASIS (RM) SET FOR SEPTEMBER 28,
2023
    * QTRLY LOSS PER SHARE $0.28
    * Q1 EARNINGS PER SHARE VIEW $-0.15 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX2XJkcm 
Further company coverage:  OCUP.O